The present study provides a compelling rational to explore therapeutic agents to inhibit TFF3 in EC and combination regimens of TAM with TFF3-inhibiting agents for hormone dependent BC, thereby preventing TAM-stimulating effects in endometrial tissues. This evidence concerns the gene TFF3 and breast cancer.